Spice drugs: cannabinoids as a new designer drugs
DOI:
https://doi.org/10.20882/adicciones.227Keywords:
Spice drugs, synthetic cannabinoids designer drugs, JWH-018, CP 47497, JWH-073, HU-210Abstract
Some smokable herbal mixtures under the brand name Spice drugs have been sold on the Internet and in specialised shops (smart shops) since 2004. The mixtures are advertised as an exotic incense blend which releases a rich aroma and not for human consumption. When smoked, Spice drugs products have been reported by some users to have effects similar to those of cannabis. Spice drugs have received intensive attention in drug forums due to the possibility to obtain a non legal substitute of cannabis. Forensic analyses have found different potent synthetic cannabinoid agonists in some Spice drugs products, as JWH- 018, CP 47497, JWH-073 and HU-210. There are few data about its pharmacological properties in animals, but nothing about its toxicity. At present, almost nothing is known about the pharmacology, toxicology and safety profile of such compounds in humans, except the opinions of consumers in internet forums. Neither the herbal ingredients of Spice drugs, nor any of the synthetic cannabinoids found in them, are internationally controlled under the 1961 or 1971 UN drug control conventions. Some European countries have recently taken legal actions to ban or otherwise control Spice drugs products and related compounds. These cannabinoid substances can be considered as new products to be added to the list of “designer drugs”.References
Buchanan JF, Brown CR. ‘Designer drugs’. A problem in clinical toxicology. Med Toxicol Adverse Drug Exp 1988; 3: 1-17.
European Monitoring Centre for Drugs and Drug Addiction. Action on new drugs briefing paper: Understanding the Spice phenomenon (a report from an EMCDDA expert meeting, 6 March 2009, Lisbon) Updated version: 9 June 2009. Disponible en: http://www.emcdda.europa.eu/html.cfm/index78154EN.html [consultado el 02/07/09].
Stafford GI, Pedersen ME, Van Staden J, Jäger A. Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J. Ethnopharmacology 2008; 119: 513–537.
Piggee C. Investigating a not-so-natural high. Anal Chem 2009; 81: 3205-3207.
Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry 2009; 44: 832 -837.
Microgram Bulletin, Volume 42, Number 3, March 2009. Disponible en: http://www.usdoj.gov/dea/programs/forensicsci/microgram/mg0309/mg0309.html. [Consultado el 22/06/09].
Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y. Identification of a Cannabinoid Analog as a New Type of Designer Drug in a Herbal Product. Chem Pharm Bull 2009; 57:439-441.
Ashton JC, Wright JL, McPartland J.M, Tyndall JDA. Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists. Curr Med Chem2008; 15: 1428-1443.
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54:161-202.
Huffman JW and Sammy G. Duncan SG. Jr. Synthesis and pharmacology of the 1’,2’-dimethylheptyl 8-THC: exceptionally potent cannabinoids. Bioorganic & Medicinal Chemistry Letters 1997; 7: 2799-2804.
Järbe TU, Hiltunen AJ, Mechoulam R. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther 1989; 250: 1000-1005.
Ottani A and Giuliani D. HU 210: A Potent Tool for Investigations of the Cannabinoid System. CNS Drug Reviews 2001; 7: 131–145.
Weissman A, Milne GM, Melvin LS Jr. Cannabimimetic Activity from CP-47,497, A Derivative of 3-Phenylcyclohexanol. J Pharmacol Exp Ther 1982; 223: 516-523.
Compton DR, Johnson MR, Melvin LS, Mar t in BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992; 260: 201-209.
Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor biding. Drug Alcohol Depend 2000; 60: 133-140.
Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, et al. Structure-Activity Relationships of Indole- and Pyrrole-Derived Cannabinoids. J Pharmacol Exp Ther 1998; 285:995-1004.
Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 1999; 16: 131-143.
Leggett JD, Aspley S, Beckett SR, D’Antona AM, Kendall DA, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 2004; 141: 253-262.
Mechoulam R, Fride E, Hanus L, Sheskin T. Anandamide may mediate sleep induction. Nature 1997; 389: 25-26.
Muccioli GG, Lambert DM. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem 2005; 12: 1361-1394.
European Medicines Agency. London, 23 October 2008 Doc. Ref. EMEA/CHMP/537777/2008. Press release. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf [consultado el 02/07/09].
Mohamad Ben Amar. Cannabinoids in medicine: Areview of their therapeutic potencial. J Ethnopharmacol. 2006.; 105: 1-25.
Mc Donald GR, Hudson AL, Dun SMJ, You H, Baker GB, Whittal RM, et al. Bioactive Contaminants Leach from Disposable Laboratory Plasticware. Science 2008; 322: 5903-5912.
